Study at a glance
What did the vitamin D and hormone studies test?
Four studies examined vitamin D and steroid hormones. Laboratory work used monkey ovarian follicles, which contain developing eggs, and pig ovarian cells. Human studies tested vitamin D3 in men selected partly for a low testosterone screening result and in women having in vitro fertilisation (IVF) fertility treatment. Exposing cells grown in the laboratory directly to active vitamin D is different from taking vitamin D3 by mouth.
What did the laboratory studies find?
Responses in monkey follicles depended on their stage of development. Later-stage exposure increased survival, size and the amounts of several hormones produced, but not every hormone or enzyme-related gene changed. In the pig-cell experiment, progesterone decreased instead. Reporting problems made that result less certain. Differences in species, cells, dose and timing prevent a simple comparison of the two directions.
Did vitamin D supplements change hormone levels in people?
A 12-week trial in 100 men raised vitamin D but did not clearly increase total testosterone or the main additional hormone measurements. The screening and final testosterone tests differed, so not all men had low testosterone by the final method. In a smaller group having IVF, vitamin D rose in the fluid around the developing eggs, but the amounts of steroid hormones measured did not clearly differ from placebo.
What do these studies tell us about hormones and fertility?
More hormone in cells grown in the laboratory could partly reflect more hormone-producing cells rather than more production by each cell. The small number of donors and the use of stimulation during IVF limit how widely the findings apply. No clear difference in the human comparisons does not prove that the results were exactly the same. These studies do not establish that vitamin D generally raises hormones, improves fertility or treats hormone-related disease. They do not provide a personal treatment plan.
Read the full article below ↓Vitamin D-related experiments can change steroid-hormone output in ovarian models, but the direction is not uniform and human trials do not reproduce every laboratory prediction. Primate follicle cultures, porcine granulosa cells, a testosterone trial and an IVF biological subset answer different questions. Their comparison shows why a change in cell behaviour cannot automatically be read as improved hormonal function or fertility in people. For the shorter account, see Vitamin D and Steroid Hormones: From Follicle Models to Human Trials: Study Summary.
Four studies, four different levels of inference
Vitamin D and Hormones includes both hormone production and responsiveness to hormonal signals. This review focuses on steroid-hormone output and measured hormone concentrations. It distinguishes experiments in isolated cells or follicles from trials in people, where absorption, metabolism, tissue distribution, feedback and the clinical setting all intervene between supplementation and the measured result.
Xu and colleagues studied rhesus macaque follicles at different developmental stages. Hong and colleagues examined immature porcine granulosa cells, the ovarian cells used in their progesterone-production experiment. Lerchbaum and colleagues tested oral vitamin D3 in men selected partly through a low testosterone screening result. Makieva and colleagues examined follicular fluid from a biological subset of an IVF trial.
These are not four estimates of a single common treatment effect. Their exposures include direct active calcitriol in culture and oral cholecalciferol in people; their outcomes include secreted hormone, gene expression and circulating or follicular-fluid concentrations. The comparison is useful precisely because these distinctions help explain what can and cannot be concluded from apparently positive or negative results.
This is an original VD3FL analysis. The main articles were examined, including their material tables and figures. Makieva’s supplementary tables were unavailable, so that paper is used only for its main-table follicular-fluid hormone comparison. Its exploratory gene-expression findings are not used here to establish a pathway or clinical benefit.
Primate follicles provide a developmental experiment
Xu’s study used ovarian material from 14 female rhesus macaques aged 6 to 14 years: eight contributed to tissue and cultured-follicle expression experiments, and six to the follicle-development experiment. The experiment examined both preantral follicles and follicles that had developed an antrum, a fluid-filled cavity. Developmental stage was therefore part of the experimental question rather than an incidental characteristic.
The culture exposure was 25 pg/mL active calcitriol, although vitamin D3 shorthand appears in the paper. Follicles received exposure either during the first two weeks, corresponding to the earlier stage, or during weeks three to five, corresponding to the later antral period. Culture conditions also included follicle-stimulating hormone and insulin. The result concerns this supported culture environment, not an isolated effect operating independently of all other hormonal inputs.
Expression of CYP2R1, CYP27B1 and VDR was detected in the studied follicles. These findings identify components associated with vitamin D metabolism and signalling. They do not directly measure the rate of local conversion through those enzymes. Why VDR Presence Is Not the Same as Vitamin D Response separates detection of signalling machinery from evidence of an actual response. The distinction is important when using Vitamin D Receptors to understand a tissue’s potential responsiveness: the presence of molecular machinery is not a measurement of how much active hormone it produces.
The study also compared expression at different stages and between cultured and in-vivo-developed follicles. Those comparisons give developmental context, but they do not establish that culture exactly reproduces the ovary’s normal hormonal environment. Tissue samples were pooled, and multiple cultured follicles came from the same animals. The number of follicles is therefore not the same as the number of independent animal donors.
PCR products were sequence-verified, and immunostaining placed VDR in oocytes and, increasingly with development, granulosa cells. In culture, calcitriol increased CYP2R1 and VDR transcripts at the preantral stage; later it also increased CYP27B1 and restored VDR expression towards the in-vivo antral comparison. These are transcript and localisation findings, not direct measurements of enzyme flux. Estradiol and progesterone in collected medium were assessed by electrochemiluminescence immunoassay, with separate ELISAs for androstenedione and anti-Müllerian hormone.
Survival and hormone output did not change together at every stage
During the preantral exposure period, follicle survival increased, while follicle diameter and anti-Müllerian hormone output did not show a corresponding significant change. This separates survival from growth and from the measured secretory outcome. It would be inaccurate to describe every aspect of early follicle development as increased by the treatment.
During antral-stage exposure, survival and diameter increased, and the culture medium contained higher estradiol, progesterone and anti-Müllerian hormone concentrations. Androstenedione did not show the same significant difference. Thus, even within the later-stage experiment, the hormone pattern was selective rather than a uniform rise in all steroid outputs.
The relevant steroidogenic transcript results were also not uniformly positive. CYP17A1 and CYP19A1 expression did not differ significantly in the reported antral comparison. A statement that calcitriol increased those transcripts would conflict with the results. The investigators observed a secretory phenotype, but did not demonstrate every proposed enzyme-level route that might account for it.
Larger follicles may contain more hormone-producing cells. Therefore, increased hormone in the culture medium does not, by itself, demonstrate increased steroid production per cell. The experiment did not use a VDR-loss intervention to establish that the output difference required that receptor. These limits do not dismiss the observed response; they define the level at which the response was actually demonstrated.
After hCG exposure, two oocytes in the supplemented antral group progressed beyond the germinal-vesicle stage (one to metaphase I and one to metaphase II) compared with none in controls. This small number cannot establish improved reproductive success. Oocyte observations, follicle survival, hormone output and live birth are different endpoints. The study provides a useful primate model of stage-dependent ovarian responses, not evidence that taking vitamin D improves human fertility.
A porcine cell study reported the opposite progesterone direction
Hong’s experiment used granulosa cells from immature pig follicles approximately 3 to 5 mm in diameter. The reported cell viability was 70 to 80%, and the donor-level replication was not clearly specified. The study used active 1,25-dihydroxyvitamin D3 at 100 nanomolar for the central culture comparison, despite the abbreviated vitamin D3 terminology in its title and text.
Progesterone in culture medium was measured by competitive enzyme immunoassay, transcripts by quantitative PCR and proteins by western blot, against an ethanol vehicle control. CYP11A1 transcript suppression developed over 8 to 24 hours; the dose experiment reported maximal suppression at 100 nanomolar. These time and dose observations concern the gene readout, not a demonstrated clinical dose-response.
Secreted progesterone decreased after exposure. CYP11A1 messenger RNA decreased, whereas expression of 3β-hydroxysteroid dehydrogenase increased. The differing enzyme-associated responses are important: steroid production cannot be understood simply by counting how many measured genes moved upward. The measured hormonal output and the individual molecular findings need to be described separately.
There is a reporting discrepancy concerning the significance of the CYP11A1 protein result between the narrative and figure account. That disputed result is not treated here as a confirmed quantitative finding. Figure-axis labelling also limits confidence in deriving a precise progesterone effect size from the graphic. The study is retained as a low-confidence example of a different observed direction, not an equal-weight estimate to be pooled with the primate experiment.
It would be tempting to explain the contrast as a difference between pigs and primates. The experiments cannot isolate species as the cause, because cell preparation, developmental stage, concentration, exposure duration and culture environment also differed. The defensible conclusion is that the two models did not show a uniform progesterone response under their respective conditions.
Neither study establishes a clinical dose-response relationship for oral cholecalciferol. Nor does the porcine experiment show that an identified VDR mechanism caused its entire progesterone response. This is a boundary on mechanism and translation, not a claim that the measured culture result is irrelevant.
A human testosterone trial tested a different proposition
Lerchbaum and colleagues conducted a placebo-controlled trial in Graz involving 100 men selected for a low screening testosterone result and 25-hydroxyvitamin D below 75 nmol/L. Participants received 20,000 IU vitamin D3 weekly or placebo for 12 weeks. Ninety-four completed the trial, with 47 in each group.
Blood was collected fasting between 8 and 9 a.m., reducing variation from sampling time. Baseline-adjusted ANCOVA compared the groups, using participants with both baseline and follow-up measurements; the reported intention-to-treat approach therefore did not supply missing follow-up outcomes for every randomised man. Planned sexual, psychological and physical symptom measures were not obtained at study end because of organisational problems, leaving symptomatic benefit untested.
The primary outcome concerned total testosterone measured using mass spectrometry. The treatment difference was −0.188 nmol/L, with a 95% confidence interval from −1.50 to 1.12 nmol/L and p=.776. This did not establish an increase in testosterone with supplementation. The confidence interval is more informative than the p value alone because it shows the range of differences compatible with the estimate and its uncertainty.
Free testosterone, free androgen index and the principal secondary hormone comparisons likewise did not show a significant treatment effect. Calculated free testosterone should not be presented as a direct laboratory assay. Exploratory subgroup observations concerning sex-hormone-binding globulin do not overturn the primary total-testosterone result.
A major qualification concerns recruitment. Screening used an immunoassay, whereas the final testosterone assessment used mass spectrometry. Median values were approximately 8.2 nmol/L with the screening method and 12.7 nmol/L with mass spectrometry. The enrolled population was consequently not uniformly characterised by low testosterone using the final analytical method.
That discrepancy changes the clinical question the trial can answer. It should not be described as a definitive treatment trial for uniformly confirmed hypogonadism. The sample was also small, treatment lasted 12 weeks, and few participants were severely vitamin-D-deficient. The result bounds a particular supplementation hypothesis without proving that vitamin D can never affect androgen physiology in any population.
Vitamin D status increased, with an adjusted between-group difference of 32 nmol/L (95% CI 23 to 41), providing evidence that the intervention altered exposure. PTH and serum and urinary calcium comparisons were null. No important harms or hypercalcaemia were reported during the twelve-week trial, which does not establish safety of different regimens. Yet the selected circulating hormone outcomes did not show the expected change. This illustrates why a biochemical supplementation response and a clinically useful hormonal response must be evaluated separately. The trial’s earlier normal-testosterone report belongs to the same research programme and should not be counted as an independent laboratory replication of this stratum.
IVF follicular fluid tests local exposure and hormone concentrations
Makieva’s study examined material from the SUNDRO trial in women undergoing IVF. The biological subset contained 145 women: 95 contributed dominant-follicle fluid samples and 50 contributed granulosa-cell material. The fluid comparison included 50 women in the vitamin D group and 45 receiving placebo.
Participants were aged 18 to 39, had body mass index 18 to 25 and baseline 25-hydroxyvitamin D below 30 ng/mL. The registered intervention was a single oral dose of 600,000 IU cholecalciferol administered two to twelve weeks before retrieval.
The article inconsistently describes the preparation using calcifediol or 25-hydroxyvitamin D terminology. The trial’s registered product, DIBASE, identifies colecalciferol, with CAS number 67-97-0, under EudraCT 2015-004233-27/IT. That registered identity is used here; this clarification is not described as a published correction to the article.
Fluid from the dominant follicle was sampled at retrieval, approximately 36 hours after hCG, and analysed by liquid chromatography: tandem mass spectrometry. Serum vitamin D used a different clinical immunoassay. The fluid assays used isotope-labelled internal standards, with duplicate testing on 10% of samples; quality-control material was plasma because follicular-fluid controls were unavailable. These details matter when comparing absolute concentrations with other studies or sample types.
Follicular-fluid 25-hydroxyvitamin D was higher in the supplemented group, approximately 39.5 versus 13.8 ng/mL. However, the main hormone table did not show significant between-group differences in estradiol, p=.75; progesterone, p=.12; or cortisol, p=.92. The other measured steroids in the main table likewise showed no significant between-group differences. Increased local vitamin D exposure therefore did not establish a corresponding increase in measured steroid concentrations.
These null comparisons are not equivalence tests. They do not prove that the groups were identical or exclude every potentially relevant difference. The biological samples were selected subsets of the parent trial, and previous IVF treatment differed between groups, approximately 44% versus 20%. Those features matter when interpreting balance and generalisability.
The follicles were sampled in a stimulated, periovulatory IVF setting. Their hormonal environment cannot be assumed to represent a natural menstrual cycle. A follicular cortisol concentration also does not measure central HPA-axis feedback. Neither pregnancy benefit nor prevention of ovarian hyperstimulation follows from the fluid hormone results.
Why the laboratory and human results are not simply contradictory
The primate experiment directly exposed cultured follicles to active hormone at selected developmental stages. The human IVF study administered a precursor orally and measured fluid after ovarian stimulation. They differ in the intervention, its route, the hormonal environment, the tissue state and the timing of measurement. A positive result in the first and a null comparison in the second need not be mutually inconsistent.
Similarly, the porcine progesterone result and the human testosterone trial concern different steroid-producing systems. They cannot be used to calculate a common percentage increase or decrease in hormonal function. The relevant synthesis is about the specificity of responses, not an average effect across incomparable outcomes.
Hormone Concentration, Receptor Response and Clinical Benefit explains the distinction between hormone concentration, receptor response and clinical benefit. That framework helps prevent an increase in one experimental output from being presented as a general improvement in endocrine health. A hormone does not become beneficial merely because its measured concentration rises; the cited studies must be interpreted according to the question and outcome they actually tested.
The wider topic of Vitamin D and Endocrine Crosstalk also includes interactions beyond steroid production. Those interactions require their own evidence rather than being inferred from ovarian or androgen results. For example, Vitamin D and Insulin Signalling concerns responsiveness to a peptide hormone, while Vitamin D and Calcium Physiology provides the mineral-regulation context in which parathyroid hormone and vitamin D are studied together.
Related questions about hormone responses
For a separate examination of glucocorticoid responsiveness, see Vitamin D, Cortisol and Glucocorticoid Responses: Full Study. It addresses a different question from the steroid-output experiments considered here.
Vitamin D, Hypothalamic Signalling and Glucose Coordination: Full Study provides the separate review of neuronal signalling and glucose coordination. For mineral-hormone feedback and compensation, see Vitamin D and Endocrine Coordination: Compensation and Failure: Full Study. Each route develops its own evidence; the four steroid studies reviewed here do not establish those mechanisms.
Taken together, the routes allow readers to distinguish production, local concentration, receptor-associated responsiveness and whole-system outcomes. The distinction is scientifically useful because a change at one level can occur without a corresponding change at another. It also makes the remaining uncertainties more specific: which tissue, which signal, which exposure and which clinically meaningful outcome would need to be tested next?
Conclusion
The selected ovarian models demonstrate context-dependent changes in hormone output, including different progesterone directions under different experimental conditions. The human testosterone and stimulated follicular-fluid comparisons did not establish the corresponding hormonal benefits. These studies support careful investigation of vitamin D: steroid interactions, but do not establish a universal hormone-raising effect, improved fertility or a treatment regimen for endocrine disease.
Primary source and publication details
Hong SH, Lee JE, Kim HS, Jung YJ, Hwang D, Lee JH, Yang SY, Kim SC, Cho SK, An BS. Effect of vitamin D3 on production of progesterone in porcine granulosa cells by regulation of steroidogenic enzymes. Journal of biomedical research. 2016;30(3):203-208. DOI 10.7555/jbr.30.2016k0012. PMID 27533930.
Lerchbaum E, Trummer C, Theiler-Schwetz V, Kollmann M, Wölfler M, Heijboer AC, Pilz S, Obermayer-Pietsch B. Effects of vitamin D supplementation on androgens in men with low testosterone levels: a randomized controlled trial. European journal of nutrition. 2019;58(8):3135-3146. DOI 10.1007/s00394-018-1858-z. PMID 30460609.
Makieva S, Reschini M, Ferrari S, Bonesi F, Polledri E, Fustinoni S, Restelli L, Sarais V, Somigliana E, Viganò P. Oral Vitamin D supplementation impacts gene expression in granulosa cells in women undergoing IVF. Human reproduction (Oxford, England). 2021;36(1):130-144. DOI 10.1093/humrep/deaa262. PMID 33305818.
Xu J, Lawson MS, Xu F, Du Y, Tkachenko OY, Bishop CV, Pejovic-Nezhat L, Seifer DB, Hennebold JD. Vitamin D3 Regulates Follicular Development and Intrafollicular Vitamin D Biosynthesis and Signaling in the Primate Ovary. Frontiers in physiology. 2018;9:1600. DOI 10.3389/fphys.2018.01600. PMID 30487754.
EU Clinical Trials Register. Vitamin D Supplementation on Assisted Reproduction Technology (ART) outcomes: a randomized clinical controlled trial and an investigation of the involved biological mechanisms. EudraCT 2015-004233-27/IT. Sponsor: Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico. Record first entered 22 November 2017. This supporting record identifies the SUNDRO intervention; it describes the same trial, not an independent study.
Related reading
Effects of vitamin D supplementation on androgens in men with low testosterone levels: a randomized controlled trial
We, therefore, aimed to evaluate whether vitamin D supplementation increases serum total testosterone (TT) levels in men with low TT levels at baseline.
Original paper ↗Read more →Vitamin D3 Regulates Follicular Development and Intrafollicular Vitamin D Biosynthesis and Signaling in the Primate Ovary
Therefore, we investigated the direct effects of VD3 at the specific preantral and antral stages of follicular development, and tested the hypothesis that vitamin D receptor (VDR) and enzymes critical for vitamin D biosynthesis are expressed in the primate ovary.
Original paper ↗Read more →Vitamin D and Steroid Hormones: From Follicle Models to Human Trials: Study Summary
A concise summary of ovarian cell studies, the testosterone trial and IVF hormone results, with the limits on claims about hormonal or fertility benefits.
Read more →Vitamin D, Calcium, Parathyroid Hormone, and Sex Steroids in Bone Health and Effects of Aging
Bone health of the elderly is a major global health concern, since about 1 in 3 women and 1 in 5 men suffer from bone loss and fractures, often called osteoporosis, in old age.
Original paper ↗Read more →A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis
The renal actions of parathyroid hormone (PTH) promote 1,25-vitamin D generation; however, the signaling mechanisms that control PTH-dependent vitamin D activation remain unknown.
Original paper ↗Read more →Arterial Structure and Function in Mild Primary Hyperparathyroidism Is Not Directly Related to Parathyroid Hormone, Calcium, or Vitamin D
We evaluated the possible vascular effects of these risk factors in patients with mild PHPT by using standard methods and new imaging techniques.
Original paper ↗Read more →Association between 25-Hydroxyvitamin D, Parathyroid Hormone, Vitamin D and Calcium Intake, and Bone Density in Healthy Adult Women: A Cross-Sectional Analysis from the D-SOL Study
This cross-sectional analysis aimed to investigate the associations of 25(OH)D and plasma PTH concentrations with bone parameters, and potential confounders, in women living in a high (England) or low (Brazil) latitude country.
Original paper ↗Read more →Associations of Vitamin D Deficiency, Parathyroid hormone, Calcium, and Phosphorus with Perinatal Adverse Outcomes. A Prospective Cohort Study
We aimed to evaluate the association of vitamin D deficiency during early pregnancy with preterm birth.
Original paper ↗Read more →Changes in the Calcium-Parathyroid Hormone-Vitamin D Axis and Prognosis for Critically Ill Patients: A Prospective Observational Study
Vitamin D deficiency is prevalent in critically ill patients and may contribute to suboptimal clinical outcomes, but little is known about alterations of the calcium-parathyroid hormone (PTH)-vitamin D axis and prognosis in these individuals.
Original paper ↗Read more →Effects of Different Dietary Interventions on Calcitriol, Parathyroid Hormone, Calcium, and Phosphorus: Results from the DASH Trial
This secondary analysis of the DASH trial aimed to determine the effect of dietary patterns on blood concentrations of calcitriol, parathyroid hormone (PTH), ionized calcium, and urinary excretion of calcium and phosphorus.
Original paper ↗Read more →Evaluation of vitamin D status, parathyroid hormone, and calcium among Iranian pregnant women with preeclampsia: A case-control study
The aim of the present study was to evaluate the association between vitamin D status and preeclampsia.
Original paper ↗Read more →Genetic association of serum calcium, phosphate, vitamin D, parathyroid hormone, and FGF23 with the risk of aortic stenosis
However, evidence of the causal role of mineral metabolism in CAVS is still lacking.
Original paper ↗Read more →Interactions between Vitamin D Status, Calcium Intake and Parathyroid Hormone Concentrations in Healthy White-Skinned Pregnant Women at Northern Latitude
Little explored in pregnancy, we aimed to examine the relative importance of serum 25-hydroxyvitamin D (25(OH)D) and calcium intake on parathyroid hormone (PTH) concentrations in healthy white-skinned pregnant women.
Original paper ↗Read more →Postprandial metabolic responses of serum calcium, parathyroid hormone and C-telopeptide of type I collagen to three doses of calcium delivered in milk
The present study investigated Ca absorption patterns with increasing levels of fortification in milk, and the response to one dose of a Ca salt.
Original paper ↗Read more →R990G Polymorphism of Calcium Sensing Receptor Gene Is Associated with High Parathyroid Hormone Levels in Subjects with Vitamin D Deficiency: A Cross-Sectional Study
Single nucleotide polymorphisms (SNPs), R990G and A986S of the calcium sensing receptor (CaSR) gene, are shown to influence response of parathyroid hormone (PTH) in subjects with optimal vitamin D levels.
Original paper ↗Read more →Serum levels of vitamin D, parathyroid hormone and calcium in relation to survival following breast cancer
The aim of this study was to examine pre-diagnostic levels of vitamin D (25OHD), PTH and calcium in relation to survival after breast cancer.
Original paper ↗Read more →The Influence of Different Cholecalciferol Supplementation Regimes on 25(OH) Cholecalciferol, Calcium and Parathyroid Hormone after Bariatric Surgery
Background and objectives: Vitamin D is an essential vitamin that plays a key role in maintaining physiological calcium balance, and is also a pivotal element in the formation of bone structure.
Original paper ↗Read more →The Role of Calcium, 25-Hydroxyvitamin D, and Parathyroid Hormone in Irritable Bowel Syndrome: A Bidirectional Two-Sample Mendelian Randomization Study
Therefore, we aimed to explore the bidirectional causal effects among serum calcium, Vit-D, PTH, and IBS at the genetic level by a two-sample Mendelian randomization (MR) analysis of the datasets from IEU OpenGWAS database.
Original paper ↗Read more →Therapeutic Plasma Exchange and Changes in Calcium, Phosphate, Parathyroid Hormone, and Fibroblast Growth Factor-23
This study examined changes in plasma and effluent levels of total calcium, phosphate, PTH, and FGF-23 in individuals undergoing TPE.
Original paper ↗Read more →Higher Proportion of Non-1-84 PTH Fragments in Peritoneal Dialysis Patients Compared to Hemodialysis Patients Using Solutions Containing 1.75 mmol/l Calcium
The prevalence of low: turnover bone disease (LTBD) in peritoneal dialysis (PD) patients is higher than in hemodialysis (HD) patients.
Original paper ↗Read more →Vitamin D Metabolites and Their Association with Calcium, Phosphorus, and PTH Concentrations, Severity of Illness, and Mortality in Hospitalized Equine Neonates
Serum 25(OH)D3 and 1,25(OH) 2D3 concentrations were significantly lower in septic and SNS compared to healthy foals (P.
Original paper ↗Read more →Original sources
Effect of vitamin D3 on production of progesterone in porcine granulosa cells by regulation of steroidogenic enzymes
Published in Journal of biomedical research (2016).
Publication details
Hong SH, Lee JE, Kim HS, Jung YJ, Hwang D, Lee JH, Yang SY, Kim SC, Cho SK, An BS. Effect of vitamin D3 on production of progesterone in porcine granulosa cells by regulation of steroidogenic enzymes. Journal of biomedical research. 2016;30(3):203-208. DOI 10.7555/jbr.30.2016k0012. PMID 27533930.
Effects of vitamin D supplementation on androgens in men with low testosterone levels: a randomized controlled trial
We, therefore, aimed to evaluate whether vitamin D supplementation increases serum total testosterone (TT) levels in men with low TT levels at baseline.
Publication details
Lerchbaum E, Trummer C, Theiler-Schwetz V, Kollmann M, Wölfler M, Heijboer AC, Pilz S, Obermayer-Pietsch B. Effects of vitamin D supplementation on androgens in men with low testosterone levels: a randomized controlled trial. European journal of nutrition. 2019;58(8):3135-3146. DOI 10.1007/s00394-018-1858-z. PMID 30460609.
Oral Vitamin D supplementation impacts gene expression in granulosa cells in women undergoing IVF
Published in Human reproduction (Oxford, England) (2021).
Publication details
Makieva S, Reschini M, Ferrari S, Bonesi F, Polledri E, Fustinoni S, Restelli L, Sarais V, Somigliana E, Viganò P. Oral Vitamin D supplementation impacts gene expression in granulosa cells in women undergoing IVF. Human reproduction (Oxford, England). 2021;36(1):130-144. DOI 10.1093/humrep/deaa262. PMID 33305818.
Vitamin D3 Regulates Follicular Development and Intrafollicular Vitamin D Biosynthesis and Signaling in the Primate Ovary
Therefore, we investigated the direct effects of VD3 at the specific preantral and antral stages of follicular development, and tested the hypothesis that vitamin D receptor (VDR) and enzymes critical for vitamin D biosynthesis are expressed in the primate ovary.
Publication details
Xu J, Lawson MS, Xu F, Du Y, Tkachenko OY, Bishop CV, Pejovic-Nezhat L, Seifer DB, Hennebold JD. Vitamin D3 Regulates Follicular Development and Intrafollicular Vitamin D Biosynthesis and Signaling in the Primate Ovary. Frontiers in physiology. 2018;9:1600. DOI 10.3389/fphys.2018.01600. PMID 30487754.
Vitamin D Supplementation on Assisted Reproduction Technology (ART) outcomes: a randomized clinical controlled trial and an investigation of the involved biological mechanisms
EU Clinical Trials Register.
Publication details
EU Clinical Trials Register. Vitamin D Supplementation on Assisted Reproduction Technology (ART) outcomes: a randomized clinical controlled trial and an investigation of the involved biological mechanisms. EudraCT 2015-004233-27/IT. Sponsor: Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico. Record first entered 22 November 2017. This supporting record identifies the SUNDRO intervention; it describes the same trial, not an independent study.